Fresenius has been given a "Buy" rating by UBS, with a target price of 34 euros.
Despite the underperformance of European medical technology shares compared to the broader market this year, analyst Graham Doyle expresses skepticism about the sector as a whole.
In a commentary released on November 26, 2024, Doyle noted that his sales and earnings forecasts for 2025 fall below consensus estimates for 10 out of the 17 sector stocks he covers.
This cautious outlook reflects ongoing challenges within the medical technology industry, which has struggled to meet market expectations.